Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
January 3, 2024Annals of Medicine and SurgeryOpen Access

Acetazolamide treatment yielded an excellent clinical response in a child with sodium channel myotonia caused by a novel Ile239Thr mutation in the SCN4A gene.

View Full Paper
Ask AI
Bookmark
Share

Comparison

Acetazolamide treatment

Design

Case report

Key result

Acetazolamide treatment yielded an excellent clinical response in a child with sodium channel myotonia caused by a novel Ile239Thr mutation in the SCN4A gene.

Authors

JYJashpal YadavRBRitesh BarnwalSMSujit Kumar Mandal

Discussion

Loading...

Member takes

Overview

Acetazolamide may be trialed cautiously in SCN4A myotonia; hypothesis-generating for the novel Ile239Thr mutation.

Study Design

Type

Case Report (n=1)

Structured PICO

P
Population
A child presenting with generalized muscle hypertrophy and stiffness diagnosed with sodium channel myotonia due to a novel Ile239Thr mutation in the SCN4A gene.
I
Intervention
Acetazolamide
O
Outcome
Clinical response to treatment

Acetazolamide can be an effective and safe treatment for sodium channel myotonia caused by a novel Ile239Thr mutation in the SCN4A gene.

Cite This Study

Yadav et al. (2024) conducted a case report in Sodium channel myotonia (n=1). Acetazolamide was evaluated on Clinical response. Acetazolamide treatment yielded an excellent clinical response in a child with sodium channel myotonia caused by a novel Ile239Thr mutation in the SCN4A gene.

synapsesocial.com/papers/6a9da2c115f03e7590bf281chttps://doi.org/10.1097/ms9.0000000000001673
View Full Paper
Ask AI
Bookmark
Share